Nicox - Continuing to move towards data inflection points
Nicox provided a mid-year business update on 16 July and reported details on the progress of its key programmes. The company’s lead internal programmes, NCX-470 and NCX-4251, continue to advance in their respective clinical trials. Top-line data from Mont Blanc, the first of two Phase III NCX-470 studies in glaucoma and ocular hypertension, is expected in Q222. Data from the second Phase III trial, Denali, are now expected in 2023 (versus Q422 previously), and we have revised our potential US launch timing estimate to H224 (vs H124 previously). Nicox recently completed final dosing and follow-up in the NCX-4251 Mississippi Phase IIb in acute blepharitis, an indication with no specific FDA-approved product to date. Top-line Mississippi data are expected in September 2021.Nicox is engaged in the ophthalmic market. Co. markets several ophthalmic products in the United States and Europe with a portfolio of therapies and diagnostic tools that can help people to enhance their sight. Co. has developed naproxcinod, the first member of the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents, for the treatment of the signs and symptoms of osteoarthritis. Beyond naproxcinod, Co. has a pipeline containing multiple nitric oxide-donating NCEs, which are in clinical development with partners for the treatment of diseases, such as hypertension, glaucoma and Chronic Obstructive Pulmonary Disease (COPD).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.